Leonardo Marzio

ORCID: 0000-0003-2304-966X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Helicobacter pylori-related gastroenterology studies
  • Gastroesophageal reflux and treatments
  • Gastrointestinal motility and disorders
  • Eosinophilic Esophagitis
  • Veterinary medicine and infectious diseases
  • Diet and metabolism studies
  • Liver Disease Diagnosis and Treatment
  • Esophageal and GI Pathology
  • Microscopic Colitis
  • Dysphagia Assessment and Management
  • Gastric Cancer Management and Outcomes
  • Inflammatory Bowel Disease
  • Liver Disease and Transplantation
  • Digestive system and related health
  • Cardiac Ischemia and Reperfusion
  • Mycobacterium research and diagnosis
  • Anesthesia and Pain Management
  • Microbial Metabolites in Food Biotechnology
  • Clostridium difficile and Clostridium perfringens research
  • Nitric Oxide and Endothelin Effects
  • Anorectal Disease Treatments and Outcomes
  • Infant Health and Development
  • Cardiac Imaging and Diagnostics
  • Autoimmune and Inflammatory Disorders
  • Gastrointestinal disorders and treatments

University of Chieti-Pescara
2005-2019

Azienda USL di Pescara
2004-2019

Ospedale di Santo Spirito
2017

Civita
2017

ASL Roma
2017

University of Rome Tor Vergata
2016

Fondazione Cassa di Risparmio Civitavecchia
2015-2016

Presidio Ospedaliero
2003

Casa di cura Pierangeli
1996-1998

Duke Medical Center
1995

Abstract An experimental rodent model was used to demonstrate the viability of coccoid form Helicobacter pylori . Concentrated suspensions were prepared for two different morphologies: at 2 days incubation bacillary forms and 20 “dormant” forms. The strains fresh isolates from humans with duodenal ulceration, collection strains. Five hundred microliters culture (OD 550 = 5 Mc Farland) (2‐5×10 9 CFU/ml) (0 morphology inoculated intragastrically in BALB/c mice. gastric mucosa mice colonized by...

10.1111/j.1348-0421.1994.tb02136.x article EN Microbiology and Immunology 1994-11-01

The aim of this work was to evaluate the antibacterial effect plant extracts as alternative and[sol ]or active agents supporting antibiotics for treating Helicobacter pylori infection. either, ethanolic or aqueous from 17 materials were studied against one H. standard strain and 11 clinical isolates using a disc diffusion test by evaluating minimum inhibitory concentration (MIC) on solid media. An activity strains recorded in large percentage tested plants. MIC values two four steps lower...

10.1002/ptr.1640 article EN Phytotherapy Research 2005-01-01

Background: Helicobacter pylori treatment failure may be due to resistance macrolides and 5‐nitroimidazoles. Aim: To test whether a preliminary in vitro susceptibility of H. tinidazole clarithromycin consequent specific regimen could improve the eradication rate. Methods: A total 109 consecutive ‐positive patients with dyspeptic symptoms were included. At endoscopy, biopsy from antrum was obtained for culture antimicrobial testing. Fifty‐six treated omeprazole, 10 days (group OTC) 53...

10.1046/j.1365-2036.2000.00870.x article EN Alimentary Pharmacology & Therapeutics 2000-12-27

Potential oxygen radical scavenging properties of the H2-receptor antagonists cimetidine, ranitidine and famotidine were investigated. These drugs, although ineffective against superoxide anion hydrogen peroxide, can scavenge hydroxyl (OH.) with a very high rate constant, which is about tenfold higher than that specific scavenger mannitol for (1.7 x 10(10) mol-1 s-1) cimetidine (1.6 s-1), displaying constant 7.5 10(9) s-1. OH. savenging effects are significant beginning from 10, 28 100 mumol...

10.1111/j.1365-2362.1994.tb02378.x article EN European Journal of Clinical Investigation 1994-07-01

Abstract Propolis and Zingiber officinale have been shown to be specifically targeted against Helicobacter pylori strains, possess antiinflammatory, antioxidant antitumoral activity used in traditional medicine for the treatment of gastrointestinal ailments. Considering that these natural products could potentially serve as novel therapeutic tools also combination with an antibiotic, aim this work was evaluate their effect when combined clarithromycin on clinical H. isolates ( n = 25),...

10.1002/ptr.1830 article EN Phytotherapy Research 2006-03-01

Two patients suffering from eosinophilic gastroenteritis (EG) were treated with sodium cromoglycate (SCG). Before treatment they showed enteric and cutaneous symptoms, such as abdominal pain, nausea, vomiting, diarrhoea recurrent urticaria angioedema. The histological findings a notable amount of infiltration in the lamina propria gastric glands, villous shortening thickening weak inflammation duodenum. 300 mg SCG, 4 times daily, for 4/5 months. During treatment, clinical symptoms...

10.1111/j.1398-9995.1990.tb00478.x article EN Allergy 1990-04-01

Little is known about prolonged effect of baclofen on oesophageal and lower sphincter (LOS) motility. We aimed at investigating the motility in gastro-oesophageal reflux disease (GORD) patients 24 h before after administration multiple doses baclofen. Twenty-one GORD underwent a 48-h manometry recording swallows, LOS During second 24-h period, received 10 mg or placebo four times per day double-blind randomized fashion. Baclofen increased basal tone comparison with baseline (P = 0.02),...

10.1111/j.1365-2982.2008.01115.x article EN Neurogastroenterology & Motility 2008-03-29

Gas and tar phases of commercially available filter cigarettes were tested for ferritin-iron-releasing effects polyunsaturated-fatty-acid oxidant capacity in vitro. A vacuum pump-dependent apparatus with Cambridge filters was used to separate gas tar; the former directly smoked into reaction mixtures, while latter extracted from aqueous medium freshly at 40 80% final concentrations. Both induced ferritin iron release, which not antagonized by superoxide dismutase (SOD). In specific...

10.1164/ajrccm.151.2.7842202 article EN American Journal of Respiratory and Critical Care Medicine 1995-02-01

Abstract Background: Levofloxacin has been proposed as an alternative to classic therapy in secondary resistance Helicobacter pylori . Aim: To evaluate primary and of H. levofloxacin, test the role susceptibility on efficacy levofloxacin‐based triple therapy. Methods: Eighty consecutive dyspeptic patients with positive 13 C‐urea breath never treated were randomly allocated into group A 1 (40 patients) B (39 patients). Eighty‐three already unsuccessfully divided 2 (51 (32 Patients underwent...

10.1111/j.1523-5378.2006.00407.x article EN Helicobacter 2006-07-13

Abstract Antibiotic resistance has resulted in unsatisfactory eradication results with dual and now triple therapy many countries. Newer antibiotics changes dosing duration of may overcome resistant strains but only provide limited improvement rates. Sequential amoxicillin (1 g twice a day) proton pump inhibitor (PPI) (twice given for 5 days followed by PPI plus clarithromycin (500 mg tinidazole is first‐line Helicobacter pylori some Standard effective regions where low. Levofloxacin based...

10.1111/j.1523-5378.2008.00639.x article EN Helicobacter 2008-08-06

Helicobacter pylori expresses an increased resistance in respect to antimicrobials currently used therapy. The aim of this study was evaluate the antimicrobial profiles H. isolates nine conventional antibiotics a Central Region (Abruzzo) Italy.Biopsies were taken from antrum and fundus 112 adult 3 children with Urea Breath Test positive dyspeptic symptoms analyzed for culture antibacterial activity. Antimicrobial susceptibility tests performed clarithromycin, metronidazole, levofloxacin,...

10.3109/00365521.2015.1092577 article EN Scandinavian Journal of Gastroenterology 2015-10-07

Abstract Aim To evaluate the therapeutic gain of addition bismuth to a rifabutin containing triple therapy with amoxicillin and pantoprazole at standard dosages for treatment third‐line Helicobacter pylori infection after preliminary susceptibility test. Methods Two separate groups patients in two pilot studies which were carried out simultaneously. One group was treated 150 mg b.i.d., 20 1 g b.i.d. 10 days other subcitrate 240 days. All underwent culture testing prior their inclusion study....

10.1111/hel.12296 article EN Helicobacter 2016-01-25

To evaluate the in vitro antimicrobial/antivirulence action of bovine lactoferrin and its ability to synergize with levofloxacin against resistant Helicobacter pylori strains analyse effect levofloxacin, amoxicillin esomeprazole without as first-line treatment for H. infection.The was analysed by MIC/MBC determination twitching motility six clinical a reference strain. The synergism evaluated using chequerboard assay. prospective therapeutic trial carried out on two separate patient groups,...

10.1093/jac/dky510 article EN cc-by-nc Journal of Antimicrobial Chemotherapy 2019-01-09

In a 6 to 12-week double-blind trial, the effect of cisapride (10 mg q.i.d.) was compared with that placebo in 63 patients esophagitis confirmed by endoscopy and/or biopsy. only one patient (3%) group but 43% (p = 0.001), symptoms had not improved after weeks. Forty continued treatment until week 12. At time, control showed significantly 0.005) higher rate healing (no erosions, ulcers, or bleeding mucosa) (63%) than (12%). 12, three 21 still moderate reflux symptoms, whereas eight 19 severe...

10.1097/00004836-198812000-00007 article EN Journal of Clinical Gastroenterology 1988-12-01
Coming Soon ...